The comparison of cyclophosphamide at different dose levels for stem cell mobilization in multiple myeloma

Basit Öğe Kaydı
dc.contributor.authorKarakus, Abdullah
dc.contributor.authorHatipoglu, Ugur
dc.contributor.authorKatircilar, Yavuz
dc.contributor.authorErkurt, Mehmet Ali
dc.contributor.authorYilmaz, Seda
dc.contributor.authorCagliyan, Gulsum Akgun
dc.contributor.authorOzturk, Fahir
dc.date.accessioned2026-04-04T13:34:47Z
dc.date.available2026-04-04T13:34:47Z
dc.date.issued2025
dc.departmentİnönü Üniversitesi
dc.description.abstractBackground: We conducted a multi-center retrospective non-randomized study to clarify roles of 2 and 3 gr/m2 doses of Cyclophosphamide (Cy) for stem cell mobilization in Multiple Myeloma. Material and methods: This study analyzed 169 adult patients who received Cy-based mobilization regimen at doses 2 and 3 gr/m2 between 2018 and 2024. All patients included in this study were 18 years old and older. Patients divided into two groups; group 1 represents 2 gr/m2 treated patients, and group 2 represents 3 gr/m2 dosing. These two groups then compared in terms of CD34+ cell number collected by apheresis, apheresis days, peak peripheral blood CD34+ value and rates of mobilization failures. Results: Higher doses of Cy yielded more hematopoietic stem cells compared to the lower dose Cy [10.00 (3.00-28.90) vs 9.01 (5.00-14.90), p = 0.002]; while mobilization failures and apheresis days were comparable across groups (p = 0.112 and p = 0.648, respectively). Apheresis days required for adequate stem cell harvest among groups was found statistically similar (p = 0.648). Conclusion: This study indicated the superior efficacy of 3 gr/m2 dose of Cy in terms of stem cell yield. However, mobilization failure and prolonged apheresis sessions were not issues with lower doses.
dc.identifier.doi10.1016/j.transci.2025.104183
dc.identifier.issn1473-0502
dc.identifier.issn1878-1683
dc.identifier.issue4
dc.identifier.orcid0000-0003-1277-5105
dc.identifier.orcid0000-0003-3836-3985
dc.identifier.orcid0000-0002-3285-417X
dc.identifier.orcid0000-0003-1381-4188
dc.identifier.pmid40627978
dc.identifier.scopus2-s2.0-105009694556
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.1016/j.transci.2025.104183
dc.identifier.urihttps://hdl.handle.net/11616/109402
dc.identifier.volume64
dc.identifier.wosWOS:001529471600002
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherPergamon-Elsevier Science Ltd
dc.relation.ispartofTransfusion and Apheresis Science
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250329
dc.subjectApheresis
dc.subjectCyclophosphamide
dc.subjectHematopoietic Stem Cell Mobilization
dc.subjectMultiple Myeloma
dc.titleThe comparison of cyclophosphamide at different dose levels for stem cell mobilization in multiple myeloma
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu